Atricure Inc. Stock
Atricure Inc. Stock
Atricure Inc. shows a slight decrease today, losing -€0.200 (-0.530%) compared to yesterday.
Atricure Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 44 € there is a slightly positive potential of 18.28% for Atricure Inc. compared to the current price of 37.2 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -0.530% | 10.714% | 24.000% | -40.000% | 9.412% | -40.000% | -40.000% |
| Orthofix Medical Inc. | -2.290% | -1.724% | -15.347% | -27.542% | -33.721% | -52.235% | -74.091% |
| Lantheus Holdings Inc | -0.340% | -0.114% | -2.676% | 86.738% | 52.622% | 38.571% | - |
| Natera Inc | 0.070% | -3.943% | 12.228% | 95.620% | 36.041% | 410.476% | 213.450% |
Comments
AtriCure (ATRC) was given a new $50.00 price target by UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure is targeting $1 billion in revenue by 2030, after reporting roughly 18% five-year compound growth, a 77%
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Karen Prange, a director of the company, sold 23,325 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC) on August 5, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4